Rein Therapeutics Inc (RNTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rein Therapeutics Inc (RNTX) has a cash flow conversion efficiency ratio of -0.295x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.42 Million) by net assets ($11.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RNTX net asset quality index to measure how much of total assets are equity-financed.
Rein Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Rein Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Rein Therapeutics Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Rein Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rein Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
kenturn Nano Tec Co Ltd
TWO:4561
|
-0.005x |
|
Jaya Konstruksi Manggala Pratama
JK:JKON
|
-0.072x |
|
Professional Computer Technology Ltd
TWO:6270
|
0.039x |
|
Fluence Corporation Ltd
AU:FLC
|
-0.541x |
|
Nature Holdings Co. Ltd.
KQ:298540
|
0.043x |
|
JMC Electronics Co Ltd
TW:6552
|
0.014x |
|
Sparebank 68 Grader Nord
OL:SB68
|
N/A |
|
Sunsuria Bhd
KLSE:3743
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Rein Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Rein Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Rein Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.92 Million | $-19.36 Million | -1.144x | -179.24% |
| 2024-12-31 | $54.39 Million | $-22.29 Million | -0.410x | +85.75% |
| 2023-12-31 | $6.89 Million | $-19.81 Million | -2.876x | -115.41% |
| 2022-12-31 | $18.62 Million | $-24.86 Million | -1.335x | -146.78% |
| 2021-12-31 | $43.90 Million | $-23.75 Million | -0.541x | +67.86% |
| 2020-12-31 | $12.16 Million | $-20.48 Million | -1.684x | -2.06% |
| 2019-12-31 | $16.05 Million | $-26.47 Million | -1.650x | -15.78% |
| 2018-12-31 | $19.60 Million | $-27.93 Million | -1.425x | -231.70% |
| 2017-12-31 | $47.80 Million | $-20.53 Million | -0.430x | -419.87% |
| 2016-12-31 | $-111.81 Million | $-15.01 Million | 0.134x | +8.16% |
| 2015-12-31 | $-94.32 Million | $-11.71 Million | 0.124x | -- |
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b a… Read more